$CGC earnings report

Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets. AlphAI read Canopy Growth's Q2 FY2027 filing as mixed. 2 quarters are on record below.

Q2 FY2027

AlphAI · Earnings readCGC · Q2 FY2027 · ended September 30, 2026

Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets

→Mixed quarter

Net revenue increased 22% and Cannabis net revenue increased 30%, led by 141% international markets cannabis growth, while consolidated gross margin declined to 29% from 33% and net loss increased to $40,694 (in thousands of Canadian dollars) following fair value charges on Canopy USA related assets.

Revenue
CA$81.4M
22% y/y
Cannabis
CA$66.2M
30% y/y
Gross margin · GAAP
29%
EPS · GAAP
$(0.10)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net revenue, three months ended September 30, 2026GAAPCA$81.37M–22%
Revenue, three months ended September 30, 2026GAAPCA$99.51M––
Excise taxes, three months ended September 30, 2026GAAPCA$18.13M––
Cost of goods sold, three months ended September 30, 2026GAAPCA$58.02M––
Gross margin, three months ended September 30, 2026GAAPCA$23.36M––
Gross margin percentage, three months ended September 30, 2026GAAP29%––
Adjusted gross margin, three months ended September 30, 2026non-GAAPCA$25.40M––
Adjusted gross margin percentage, three months ended September 30, 2026non-GAAP31%––
Selling, general and administrative expenses, three months ended September 30, 2026GAAPCA$39.69M–9% higher
Share-based compensation, three months ended September 30, 2026GAAPCA$4.03M––
Loss on asset impairment and restructuring, three months ended September 30, 2026GAAPCA$2.59M––
Total operating expenses, three months ended September 30, 2026GAAPCA$46.32M––
Operating loss, three months ended September 30, 2026GAAP−CA$22.96M––
Other income (expense), net, three months ended September 30, 2026GAAP−CA$18.53M––
Loss before income taxes, three months ended September 30, 2026GAAP−CA$41.49M––
Income tax recovery (expense), three months ended September 30, 2026GAAPCA$800K––
Net loss, three months ended September 30, 2026GAAP−CA$40.69M–increased by $35.7 million
Basic and diluted loss per share, three months ended September 30, 2026GAAP$(0.10)––
Basic and diluted weighted average common shares outstanding, three months ended September 30, 2026GAAP423,109,807––
Adjusted EBITDA, three months ended September 30, 2026non-GAAP−CA$2.88M–improvement of $0.2M or 6%
Net cash used in operating activities, three months ended September 30, 2026GAAP−CA$12.57M––
Purchases of and deposits on property, plant and equipment, three months ended September 30, 2026GAAP−CA$2.98M––
Free cash flow, three months ended September 30, 2026non-GAAP−CA$15.55M–decreased from $19.2M in Q2 FY2026 to $15.5M in Q2 FY2027
Net cash used in operating activities, six months ended September 30, 2026GAAP−CA$37.58M––
Purchases of and deposits on property, plant and equipment, six months ended September 30, 2026GAAP−CA$3.71M––
Cash and cash equivalents, September 30, 2026GAAPCA$247.3M––
Short-term investments, September 30, 2026GAAPCA$72.45M––
Current portion of long-term debt, September 30, 2026GAAPCA$43.13M––
Long-term debt, September 30, 2026GAAPCA$202.7M––

Segments

SegmentRevenueq/qy/y
CannabisGrowth was led by Canadian medical cannabis, Canadian adult-use cannabis and international markets cannabis.CA$66.23M–30%
Canadian adult-use cannabisPrimarily attributable to increased flower sales driven by the acquisition of MTL Cannabis, partially offset by declines in opportunistic bulk sales.CA$28.13M–17%
Canadian medical cannabisDriven by growth in the number of insured customers and the acquisition of MTL Cannabis, partially offset by the Canadian government’s reduction in the Veterans Affairs Canada reimbursement rate for medical cannabis.CA$25.84M–18%
International markets cannabisPrimarily due to strong sales in Europe, specifically in Germany and Poland.CA$12.27M–141%
Storz & BickelThe decrease is primarily attributable to decreased customer spending on Storz & Bickel products in certain geographic regions.CA$15.14M–(4%)

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

What drove it

  • International markets cannabis net revenue increased 141%, primarily due to strong sales in Germany and Poland.
  • Canadian medical cannabis net revenue increased 18%, driven by insured-customer growth and the MTL Cannabis acquisition.
  • Canadian adult-use cannabis net revenue increased 17%, primarily due to increased flower sales driven by the MTL Cannabis acquisition.
  • The Smiths Falls facility received EU GMP certification, and the Kincardine cultivation facility received renewed EU GMP certification.
  • The Company expanded medical cannabis supply into the United Kingdom and broadened its Australian medical cannabis portfolio.

Concerns

  • Consolidated gross margin percentage declined to 29% from 33%, and adjusted gross margin percentage declined to 31% from 33%.
  • Cannabis adjusted gross margin percentage declined to 29% from 31%, primarily attributable to the reduction in the VAC reimbursement rate available for medical cannabis.
  • Storz & Bickel net revenue declined 4% due to decreased customer spending in certain geographic regions.
  • Net loss increased by $35.7 million due to $35.8 million of fair value charges on Canopy USA related assets.
  • The filing identifies a material weakness in internal control over financial reporting and references the March 31, 2026 restatement of consolidated financial statements.

What to watch

  • Progress toward reporting positive adjusted EBITDA during fiscal 2027.
  • The impact of the VAC reimbursement-rate reduction on Cannabis segment gross margin.
  • International medical cannabis sales momentum in Germany, Poland, the United Kingdom and Australia.
  • Cultivation consistency and output improvements from capital expenditures at production facilities.
  • Customer spending trends for Storz & Bickel products in certain geographic regions.

Balance sheet and cash flow

  • Cash and cash equivalents were $247,340 (in thousands of Canadian dollars) at September 30, 2026, compared with $364,683 (in thousands of Canadian dollars) at March 31, 2026.
  • Short-term investments were $72,451 (in thousands of Canadian dollars) at September 30, 2026, compared with - at March 31, 2026.
  • Current portion of long-term debt was $43,130 (in thousands of Canadian dollars) at September 30, 2026, compared with $16,237 (in thousands of Canadian dollars) at March 31, 2026.
  • Long-term debt was $202,734 (in thousands of Canadian dollars) at September 30, 2026, compared with $217,123 (in thousands of Canadian dollars) at March 31, 2026.
  • Net cash used in operating activities was $(37,581) (in thousands of Canadian dollars) for the six months ended September 30, 2026, compared with $(28,316) (in thousands of Canadian dollars) for the six months ended September 30, 2025.
  • Net decrease in cash and cash equivalents was $(117,343) (in thousands of Canadian dollars) for the six months ended September 30, 2026, compared with net increase in cash and cash equivalents of $184,247 (in thousands of Canadian dollars) for the six months ended September 30, 2025.

Analysis

Canopy Growth reported $81,373 (in thousands of Canadian dollars) of net revenue for Q2 FY2027, versus $66,683 (in thousands of Canadian dollars) in Q2 FY2026. The Cannabis segment generated $66,235 (in thousands of Canadian dollars), up 30%, while Storz & Bickel generated $15,138 (in thousands of Canadian dollars), down 4%. International markets cannabis was the largest growth contributor, increasing 141% to $12,268 (in thousands of Canadian dollars), with the company attributing the increase to Europe, specifically Germany and Poland.

Canadian medical cannabis revenue was $25,840 (in thousands of Canadian dollars), up 18%, supported by insured-customer growth and the MTL Cannabis acquisition. Canadian adult-use cannabis revenue was $28,127 (in thousands of Canadian dollars), up 17%, primarily from increased flower sales associated with MTL Cannabis. The MTL transaction also increased selling, general and administrative expenses, which were $39,693 (in thousands of Canadian dollars), 9% higher than the prior-year period, although the company cited headcount reductions and other cost initiatives as offsets.

Margin performance deteriorated despite revenue growth. Consolidated gross margin percentage was 29%, compared with 33%, and adjusted gross margin percentage was 31%, compared with 33%. Cannabis gross margin percentage was 26%, compared with 31%, and its adjusted gross margin percentage was 29%, compared with 31%. Management attributed the Cannabis adjusted-margin decline primarily to the lower VAC reimbursement rate. Storz & Bickel gross margin percentage improved to 39% from 38% despite lower revenue, which the company attributed to cost efficiencies and product mix.

Net loss was $(40,694) (in thousands of Canadian dollars), compared with $(4,978) (in thousands of Canadian dollars), as the company cited $35.8 million of fair value charges on Canopy USA related assets. Adjusted EBITDA improved to $(2,878) (in thousands of Canadian dollars) from $(3,049) (in thousands of Canadian dollars). Free cash flow was $(15,547) (in thousands of Canadian dollars), compared with $(19,205) (in thousands of Canadian dollars), while cash and cash equivalents stood at $247,340 (in thousands of Canadian dollars) at September 30, 2026.

The release did not provide quantified financial guidance. Management stated that it is within reach of reporting positive adjusted EBITDA during fiscal 2027. Operationally, the company expanded its EU GMP-certified supply chain through Smiths Falls certification, renewed Kincardine certification, entered the United Kingdom medical market through GROW Group U.K. Ltd., and broadened its Australian medical cannabis portfolio. These initiatives place international execution, Cannabis margins and the path from adjusted EBITDA loss to positive adjusted EBITDA at the center of the reported outlook.

Management, verbatim

We have made tremendous progress on our international strategy. Our international business delivered 141% net revenue growth in the second quarter of fiscal year 2027 driven by strong medical cannabis sales in Germany and Poland. We entered the U.K. market, added to our German leadership team, broadened our product portfolio in Australia and expanded our end-to-end EU GMP-certified supply chain through the certification of our Smiths Falls facility. We expect the ongoing elevation of our cultivation capabilities to drive our momentum further across the entire business.

Luc Mongeau, Chief Executive Officer

We reported another quarter of strong net revenue growth, including a 17% year-over-year increase in Canada adult-use cannabis, an 18% increase in Canada medical cannabis and 30% growth in the Cannabis segment overall. We are progressing steadily to profitability, quarter after quarter. Our disciplined approach continues to show improvements in adjusted EBITDA 1 compared to Q2 FY2026, placing us within reach of reporting positive adjusted EBITDA during fiscal 2027.

Tom Stewart, Chief Financial Officer

Not in the filing

stated, not guessed
  • Quantified forward financial guidance for revenue, gross margin, operating expenses, tax rate, adjusted EBITDA or cash flow was not provided.
  • Prior outlook was not provided.
  • Dividends and share repurchases were not reported.
  • GAAP operating income was not reported because the company reported operating loss.
  • Adjusted EPS was not reported.
  • Quarterly cash balance comparison with the immediately preceding quarter was not reported.
  • Segment operating income or loss was not reported.
  • Operating margin was not reported.
  • Net debt was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q1 FY2027

AlphAI · Earnings readCGC · Q1 FY2027 · ended June 30, 2026

Canopy Growth Reports First Quarter Fiscal Year 2027 Financial Results; Delivers 13% Net Revenue Growth with Contributions from All Businesses

→Mixed quarter

Consolidated net revenue grew 13%, every reported business grew, adjusted gross margin improved to 31%, and adjusted EBITDA loss narrowed 59%. Offsetting these gains, cannabis gross margin declined to 22%, the VAC reimbursement-rate reduction pressured medical cannabis, and free cash outflow increased to $25.7M from $11.6M.

Revenue
CA$81.2M
increased by 13% y/y
Canada medical cannabis
CA$25.8M
an increase of 22% y/y
Gross margin · GAAP
27%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Consolidated net revenueGAAPCA$81.2M–increased by 13%
Cannabis net revenueGAAPCA$65.1M–an increase of 14%
Storz & Bickel net revenueGAAPCA$16.1M–a 6% increase
Consolidated gross marginGAAP27%––
Consolidated adjusted gross marginnon-GAAP31%––
Cannabis gross marginGAAP22%––
Cannabis adjusted gross marginnon-GAAP26%––
Storz & Bickel gross marginGAAP48%––
Inventory step-up charges related to the acquisition of MTL CannabisotherCA$2.6M––
Selling, general and administrative expensesGAAP6% higher than in Q1 FY2026–6% higher
Net lossGAAP68% lower compared to Q1 FY2026–68% lower
Adjusted EBITDA lossnon-GAAPCA$3.2M–an improvement of $4.7M or 59%
Free cash outflownon-GAAPCA$25.7M–increased from $11.6M in Q1 FY2026 to $25.7M in Q1 FY2027

Segments

SegmentRevenueq/qy/y
Canada medical cannabisGrowth in the number of insured customers and the acquisition of MTL Cannabis, partially offset by the Canadian government's reduction in the Veterans Affairs Canada reimbursement rate for medical cannabis.CA$25.8M–an increase of 22%
Canada adult-use cannabisIncreased flower sales driven by the acquisition of MTL Cannabis, partially offset by declines in opportunistic bulk sales.CA$29.7M–an increase of 10%
International markets cannabisStrength in Europe, specifically in Poland.CA$9.6M–increased 10%
Storz & BickelPrior-year product portfolio expansion and increasing sales across non-core markets.CA$16.1M–a 6% increase

What drove it

  • Consolidated net revenue increased by 13%, with reported growth in Canada medical cannabis, Canada adult-use cannabis, international markets cannabis, and Storz & Bickel.
  • The acquisition of MTL Cannabis contributed to Canada medical cannabis growth, adult-use flower sales, increased supply of high-quality flower, expanded revenue opportunities, and anticipated synergies.
  • Adjusted EBITDA loss improved primarily because of revenue growth across both segments and continued cost savings.
  • Storz & Bickel gross margin increased due to a cost-rationalization exercise implemented at the end of fiscal 2026 and recovery of certain U.S. tariffs in the period.

Concerns

  • The Canadian government's reduction in the VAC reimbursement rate partially offset Canada medical cannabis growth and cannabis adjusted gross-margin improvement.
  • Cannabis gross margin was 22% in Q1 FY2027, compared to 24% in Q1 FY2026.
  • Selling, general and administrative expenses were 6% higher than in Q1 FY2026, driven by the addition of MTL Cannabis operations.
  • Free cash outflow increased to $25.7M from $11.6M, primarily due to the timing of changes in working capital items.
  • The Q1 FY2027 adjusted gross margin excluded $2.6 million of inventory step-up charges related to the acquisition of MTL Cannabis.

What to watch

  • Completion of the MTL Cannabis integration and the realization of anticipated synergies.
  • Management anticipates further improvements in financial results, especially in the second half of fiscal 2027, as the integration is completed.
  • The impact of the VAC reimbursement-rate reduction on medical cannabis revenue and cannabis margins.
  • Working-capital movements and their effect on free cash outflow.
  • Sustained growth in Europe, specifically Poland, and sales across Storz & Bickel non-core markets.

Balance sheet and cash flow

  • Free cash outflow increased from $11.6M in Q1 FY2026 to $25.7M in Q1 FY2027, reflecting increased cash used in operating activities, primarily due to the timing of changes in working capital items.

Analysis

Canopy Growth reported $81.2M of consolidated net revenue in Q1 FY2027, up 13% compared with Q1 FY2026. Revenue increased across each reported business, including 22% growth in Canada medical cannabis, 10% growth in Canada adult-use cannabis, 10% growth in international markets cannabis, and 6% growth at Storz & Bickel. The cannabis business generated $65.1M of net revenue, while Storz & Bickel generated $16.1M.

The MTL Cannabis acquisition was a central growth driver in Canada medical cannabis and adult-use flower sales. Medical growth also reflected an increase in insured customers, while international markets benefited from strength in Europe, specifically Poland. Adult-use results were partially offset by lower opportunistic bulk sales. Storz & Bickel growth reflected prior-year product portfolio expansion and increasing sales across non-core markets.

Profitability improved on an adjusted basis, with consolidated adjusted gross margin increasing to 31% from 25% and adjusted EBITDA loss narrowing to $3.2M, an improvement of $4.7M or 59%. Consolidated gross margin increased to 27% from 25%. However, cannabis gross margin declined to 22% from 24%, while the cannabis adjusted gross margin rose to 26% from 24%. The adjusted result excludes $2.6 million of inventory step-up charges related to MTL Cannabis that were not present in the prior-year period. Storz & Bickel gross margin improved to 48% from 29%, supported by cost rationalization and recovery of certain U.S. tariffs.

Cost discipline helped offset the addition of MTL Cannabis operations, although selling, general and administrative expenses were 6% higher than in Q1 FY2026. The VAC reimbursement-rate reduction remained a specific pressure on medical cannabis revenue and cannabis margins. The company also remained cash consumptive, with free cash outflow increasing from $11.6M to $25.7M because of increased cash used in operating activities, primarily driven by the timing of working-capital changes.

No formal forward financial guidance was provided in the filing text. Management stated that it anticipates further improvement in financial results, especially in the second half of fiscal 2027, as MTL Cannabis integration is completed. The main reported execution markers are completion of that integration, synergy realization, cultivation supply expansion, the impact of VAC reimbursement changes, and the development of free cash outflow.

Management, verbatim

The renewed focus and strong momentum we established over the past year have continued into fiscal 2027. In the first quarter, we achieved net revenue growth in every business through solid execution across the organization. We have clear strategies to deliver further growth in each of our end markets. At the heart of our cannabis strategy is our company-wide push to elevate cultivation and produce a consistent and increasing supply of high-quality flower that will support growing demand both in Canada and internationally.

Luc Mongeau, Chief Executive Officer

The combination of top-line growth and disciplined cost management is enabling us to make steady progress on key profitability measures including gross margin and adjusted EBITDA. As expected, the integration of MTL Cannabis is leading to increased supply of high-quality flower, expanded revenue opportunities and the realization of meaningful synergies. We anticipate further improvements in our financial results, especially in the second half of fiscal 2027, as the integration is completed.

Tom Stewart, Chief Financial Officer

Not in the filing

stated, not guessed
  • Formal forward revenue, gross-margin, operating-expense, tax-rate, EPS, adjusted EBITDA, or free-cash-flow guidance was not provided.
  • Previous outlook was not provided.
  • Actual GAAP net loss amount was not provided.
  • GAAP and non-GAAP EPS were not provided.
  • Operating income or loss was not provided.
  • Actual selling, general and administrative expense amount was not provided.
  • Operating cash flow amount was not provided.
  • Cash, cash equivalents, debt, and other balance-sheet liquidity figures were not provided.
  • Share repurchases, dividends, and other capital-return figures were not provided.
  • Prior-quarter comparisons were not provided for the reported metrics.
  • Prior-year dollar amounts for consolidated revenue, cannabis revenue, Storz & Bickel revenue, and adjusted EBITDA loss were not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CGC earnings dates

When is Canopy Growth's next earnings date?
AlphAI has no date for CGC yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.